AI in Oncology Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

AI in Oncology Market Overview

AI is transforming oncology by improving early cancer detection, enhancing diagnostic accuracy, and enabling personalized treatment planning. It analyzes medical imaging, genomic data, and clinical records to identify patterns that support precise decision-making. AI also accelerates drug discovery, optimizes clinical trials, and predicts treatment responses, reducing time and costs. Additionally, it enables real-time patient monitoring and risk assessment, improving outcomes and survival rates. By streamlining workflows and reducing human error, AI enhances efficiency across oncology care, supporting better patient management and advancing precision oncology globally. The market reached a value of approximately USD 4.65 Billion in 2025.

AI in Oncology Market Growth Drivers

AI-Powered Oncology Platform Launches Driving the Market Value

Rising demand for faster drug discovery and precision oncology solutions is a key market driver. For instance, in September 2025, Eli Lilly launched an AI-powered platform designed to accelerate drug discovery, including oncology-focused therapeutic development. This innovation highlights how AI is being integrated into core R&D processes to improve biomarker identification and reduce development timelines. Such product launches are expected to significantly drive market growth by enhancing research efficiency, lowering costs, and enabling faster delivery of novel cancer treatments.

AI in Oncology Market Trends

Key trends shaping the market include rising AI adoption, regulatory support, increasing R&D investments, growing precision oncology demand, and advancements in AI-assisted diagnosis and data-driven clinical decision-making.

Regulatory Support for AI Adoption Boosting the Market Demand

Growing emphasis on ethical research practices and faster drug development is shaping market trends. For instance, in September 2025, the FDA supported increased adoption of AI in drug discovery, particularly in oncology, to reduce reliance on animal testing and accelerate therapeutic development timelines. This trend reflects a broader regulatory shift toward integrating AI into core research processes. Such support is expected to advance market development by encouraging innovation, improving efficiency, and promoting wider adoption of AI-driven approaches in cancer treatment discovery and development, including advancements in radiology AI and oncology imaging.

AI in Oncology Market Segmentation

AI in Oncology Market Share

Hardware Leads the Market Segment by Component

The market is witnessing strong growth across multiple components, with hardware playing a crucial enabling role. Based on component, the hardware segment led the market with the largest revenue share of over 40% in the historical period, driven by increasing demand for high-performance computing, GPUs, and specialized processors required for complex oncology data analysis. These technologies support oncology imaging, diagnostics, and real-time analytics, enhancing clinical decision-making. Additionally, advancements in computational infrastructure and growing adoption of AI-powered diagnostic tools continue to reinforce the dominance of hardware within the market.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Global AI in Oncology Market Analysis by Region

The market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, with varying levels of adoption and growth. North America dominated the market with the largest revenue share of approximately 45% in the historical period, supported by advanced healthcare infrastructure, strong research funding, and early adoption of AI technologies, particularly in cancer screening and tumor detection. The presence of leading technology and pharmaceutical companies further strengthens regional leadership. Meanwhile, Asia Pacific is expected to experience rapid growth due to increasing cancer burden and expanding healthcare investments, along with rising adoption of radiology AI and digital pathology solutions.

Leading Players in the AI in Oncology Market

Other key players in the market are Azra AI, IBM Corporation, Siemens Healthineers AG, Intel Corporation, Digital Diagnostics Inc., Medtronic plc., and Median Technologies.

Key Questions Answered in the AI in Oncology Market

• What was the AI in oncology market value in 2025?
• What is the AI in oncology market forecast outlook for 2026-2035?
• What major factors aid the demand for AI in oncology market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major AI in oncology market trends?
• Which component is expected to dominate the market segment?
• Which cancer type is anticipated to drive the market segment?
• Which application is likely to dominate the market segment?
• Which treatment is likely to dominate the market segment?
• Who are the key players in the AI in oncology market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?